Molbio Diagnostics on Monday announced the launch of a strong collaboration with Niramai Health Analytix, a Bangalore-based deep-tech startup. This partnership aims to accelerate the adoption of Niramai’s innovative AI-based non-invasive breast cancer screening solution, Thermalytix in developing countries around the world, it stated.
According to the World Health Organization (WHO), breast cancer is the most common cancer in the world and among top-5 deadliest cancers globally. Although it affects people of all sexes, it impacts women disproportionately – being among the leading causes of death in women and accounts for 24.5% of all new cancer cases in women worldwide. Late diagnosis of breast cancer is one of the challenges.
Portable point of care (POC) breast cancer screening solutions that enable efficient screening of large populations, especially in low-resource settings, is a critical healthcare need across many geographies today. Niramai’s Thermalytix is able to bridge these crucial gaps through its unique features.
Considering the high prevalence of breast cancer cases, it is important to screen populations at a large scale, which is possible only by deploying portable, non-invasive diagnostic devices like Thermalytix at point of care.
“Thermalytix uses thermal scanning coupled with smart automated AI-enabled software that is able to detect early signs of breast cancer which otherwise would not have been detected through traditional methods. Another unique feature of Thermalytix is that it enables non-touch screening and is aligned with the privacy needs of patients, thereby overcoming hesitation for breast examination. Additionally, this imaging method is radiation-free, painless, and suitable to all age groups, even young women with dense breasts,” the company said in a statement.
Through this collaboration, Molbio will promote and distribute Thermalytix in both public and private healthcare markets globally. The partnership builds on the strengths of the two companies to bring cutting-edge technology that would make high-quality diagnostics accessible to everyone.
“We are thrilled to add another cap to our universal access portfolio of innovative healthcare solutions. Niramai’s AI-based Thermalytix device for breast cancer and Molbio’s Truenat HPV-HR test for cervical cancer will enable point of care screening and early detection of the two most deadly cancers of women worldwide, saving millions of lives,” Sriram Natarajan, Vice President – Sales & Marketing of Molbio Diagnostics said in a statement.
